tiprankstipranks
Bioxcel Therapeutics Senior VP Wiley Transitions to Consultant
Company Announcements

Bioxcel Therapeutics Senior VP Wiley Transitions to Consultant

Pick the best stocks and maximize your portfolio:

Bioxcel Therapeutics ( (BTAI) ) has provided an update.

Matthew Wiley, Senior Vice President and Chief Commercial Officer of BioXcel Therapeutics, has agreed to step down from his role effective October 2, 2024, and transition to a consultancy role. He will receive severance benefits including a pro-rated bonus for 2024, nine months of his base salary, and COBRA premium reimbursements. Additionally, Wiley will consult for BioXcel at $330 per hour plus expenses until December 31, 2024, unless the agreement is terminated earlier.

For an in-depth examination of BTAI stock, go to TipRanks’ Stock Analysis page.

Related Articles
TheFlyBioXcel Therapeutics prices 5.6M shares at 48c in public offering
TipRanks Auto-Generated NewsdeskBioxcel Therapeutics Restructures Credit and Strengthens Leadership
TheFlyBioXcel announces common stock and warrants offering, no amount given
Looking for investment ideas? Subscribe to our Smart Investor newsletter for weekly expert stock picks!
Get real-time notifications on news & analysis, curated for your stock watchlist. Download the TipRanks app today! Get the App